

UN
82
052e
2006

EFFICIENT SYNTHESIS OF N⁹-ALKYLGUANINES

&

**EVALUATION OF A MORE HIGHLY CONJUGATED ANALOG OF
GUANIDINIUM-RICH MOLECULAR TRANSPORTERS USING A pH DEPENDENT
FLUORESCENCE ASSAY**

By

David E. Olsen

**Submitted in partial fulfillment
of the requirements for
the Department of Chemistry**

UNION COLLEGE

June, 2006

TABLE OF CONTENTS

<u>Section</u>	<u>Page Number</u>
I. Title Page	i
Abstracts	ii
Table of Contents	iii
II. EFFICIENT SYNTHESIS OF N⁹-ALKYLGUANINES	
Abstract	1
Introduction, Results, Discussion	1
Experimental	4
References	8
Figure 1	10
Scheme 1	11
Scheme 2	12
Title for running head	13
Graphical Abstract	14
III. EVALUATION OF A MORE HIGHLY CONJUGATED ANALOG OF GUANIDINIUM-RICH MOLECULAR TRANSPORTERS USING A pH DEPENDENT FLUORESCENCE ASSAY	
Abstract	15
Introduction	15
Experimental	18
Preliminary Results	21
References	22
Scheme 1	24
IV. Acknowledgements	25

ABSTRACT

OLSON, DAVID E. Efficient Synthesis of *N*⁹-alkylguanines. Department of Chemistry, June 2006.

Synthesis of *N*⁹-(2-chloroethyl)guanine from 2-amino-6-chloropurine was accomplished in three steps with an overall yield of 83%. All products were purified via crystallization and no chromatography was required. Selective crystallization of the desired *N*⁹ isomer subsequent to the key alkylation step completely and efficiently removed the *N*⁷ isomer. This compound was shown to be a versatile reagent in the synthesis of various *N*⁹-substituted guanines.

&

OLSON, DAVID E. Evaluation of a More Highly Conjugated Analog of Guanidinium-Rich Molecular Transporters Using a pH Dependent Fluorescence Assay. Department of Chemistry, June 2006.

The importance of the guanidino functional group in the cellular uptake of guanidinium-rich molecular transporters has been thoroughly demonstrated. Its ability to act as a bidentate hydrogen bond donor appears to play a key role in this process, but the effect of polarizability on cellular internalization has not been determined. We report the synthesis of a peptoid molecular transporter containing more highly conjugated guanine headgroups and its subsequent evaluation using a pH dependent fluorescence assay.

Efficient Synthesis of N⁹-alkylguanines

David E. Olson, J. Gregory Reid, and Joanne D. Kehlbeck*

Department of Chemistry, Union College, Schenectady, NY 12308

ABSTRACT

Synthesis of N⁹-(2-chloroethyl)guanine from 2-amino-6-chloropurine was accomplished in three steps with an overall yield of 83%. All products were purified via crystallization and no chromatography was required. Selective crystallization of the desired N⁹ isomer subsequent to the key alkylation step completely and efficiently removed the N⁷ isomer. This compound was shown to be a versatile reagent in the synthesis of various N⁹-substituted guanines.

Keywords: N⁹-(2-chloroethyl)guanine; N-alkylation; anti-virals; N-substituted guanines.

The antiviral properties of N-substituted guanines are well known.^[1-6] In particular, acyclovir and its analogs have received much attention.^[7-11] Penciclovir and its pro-drug famciclovir have been shown to be effective anti-virals against varicella-zoster virus (VZV) and herpes simplex virus (HSV)^[12], while entecavir has shown potent activity against hepatitis B virus (HBV).^[13] Ganciclovir, another member of this class of

* Correspondence: J. D. Kehlbeck, Department of Chemistry, Union College, Schenectady, NY 12308, United States of America; E-mail: kehlbecj@union.edu

compounds, has been used to treat cytomegalovirus (CMV) retinitis in immunocompromised patients.^[14]

N⁹-alkylsubstitution is a common structural motif in all of these guanine derivatives. However, selective N⁹-alkylation has proven to be a synthetic challenge. Previous syntheses of N⁹-substituted guanines have relied on the use of chromatography to separate the N⁷ and N⁹ regioisomers^[15,16], but this method of separation is both burdensome and time-consuming. When 3-bromopropane-1,1,1-tricarboxylate was used as an alkylating agent, the N⁹ isomer could be separated by crystallization, thus avoiding the use of chromatography.^[17] Also, selective N⁹-substitution has been achieved by using a blocking group at the N⁷ position^[18] as well as by the selective Pd-catalyzed allylation at the N⁹ position.^[19]

Herein, we report the facile synthesis of a functionalized N⁹-alkyl guanine, namely N⁹-(2-chloroethyl)guanine. Reaction of N⁹-(2-chloroethyl)guanine with various nucleophiles may allow for the preparation of other N⁹-substituted guanine derivatives with desirable medicinal properties.

The synthesis of N⁹-(2-chloroethyl)guanine, **4**, is shown in Scheme 1. Conversion of 2-amino-6-chloropurine into the corresponding tetrabutylammonium salt, **1**, was accomplished in quantitative yield by the method of Bisacchi *et al.*^[20] Next, N-alkylation was achieved by using an excess of 1-bromo-2-chloroethane, an inexpensive alkylating agent, under mild conditions. The reaction yielded a 5:1 ratio of regioisomers **2** and **3**,

the N⁷ and N⁹ substitution products, respectively. Recrystallization of the crude product from methylene chloride provided regioisomer **3** exclusively, thus eliminating the use of chromatography. Finally, hydrolysis of **3** in aqueous hydrochloric acid produced N⁹-(2-chloroethyl)guanine, **4**, in nearly quantitative yield.

Many N-substituted guanines are easily accessible by the reaction of N⁹-(2-chloroethyl)guanine with various nucleophiles. A few examples are reported in Scheme 2 and demonstrate the synthetic versatility of this compound. It should be noted that all nucleophilic substitution reactions involving N⁹-(2-chloroethyl)guanine reported herein were not optimized.

N⁹-(2-chloroethyl)guanine reacts smoothly with sodium iodide in DMF to provide the corresponding iodide. Not surprisingly, reaction of other nucleophiles with the iodide was considerably faster than with the chloride, so iodide catalysis was employed with subsequent nucleophiles. These reactions were run in DMSO-*d*₆, allowing them to be monitored by ¹H-NMR. ¹H-NMR analysis indicated that the first equivalent of either the amine, cyanide, thiolate, or carboxylate nucleophile resulted in the initial deprotonation of the lactam. Therefore, addition of a second equivalent was necessary to achieve the desired displacement.

All but one of the S_N2 reactions proceeded smoothly. Complications arose in the reaction with tetraethylammonium cyanide. Partial conversion to what is believed to be the desired substitution product was initially observed by ¹H-NMR at 75 °C, but this

intermediate was degraded to products lacking the characteristic ethyl triplets observed in the $^1\text{H-NMR}$ spectra of the other N^9 -substituted products. We believe the desired product underwent elimination forming guanine and acrylonitrile. $^1\text{H-NMR}$ analysis revealed succinonitrile, which would be expected from the addition of excess HCN to acrylonitrile.

In conclusion, we have demonstrated a facile and efficient synthesis of N^9 -(2-chloroethyl)guanine that avoids the use of chromatography. This compound is a versatile intermediate and can be used to synthesize other N^9 -substituted guanines via nucleophilic substitution reactions.

EXPERIMENTAL

General

All purchased reagents were used without further purification. Thin-Layer Chromatography (TLC) was performed on Selecto Scientific Silica Gel 60, F-254 TLC plates. Melting points were obtained using a Laboratory Devices MEL-TEMP and are uncorrected. $^1\text{H-NMR}$ spectra were obtained using a Varian Gemini-200 (200 MHz). Chemical shifts are reported as δ in ppm. All $^1\text{H-NMR}$ spectra are referenced to the solvent residual peak of $\text{DMSO-}d_6$ (δ 2.50) unless otherwise noted.

Tetrabutylammonium 2-amino-6-chloropurin-9-ide (1). Procedure was adapted from Bisacchi *et al.* Aqueous tetrabutylammonium hydroxide (~1.5 M, 39.3 mL, ~59 mmol)

was added to a slurry of 2-amino-6-chloropurine (10.0 g, 59 mmol) in 250 mL of CH_2Cl_2 . The reaction mixture was stirred for 30 min and the solvent removed *in vacuo*. Concentration from toluene (3 x 100 mL) allowed for the removal of water and resulted in crystallization. The solid was triturated with 200 mL of ether, filtered, washed with ether, and dried under vacuum over CaSO_4 to yield **1** (24.4 g, 59 mmol, 100%). The orange solid was used without further purification: mp 66-70 °C; R_f = 0.60 (CHCl_3 :EtOAc:EtOH 1:1:1); $^1\text{H-NMR}$ (CDCl_3 , referenced to TMS δ 0.00) δ 0.90 (12H, t), 1.28 (16H, m), 2.90 (12H, m), 7.40 (2H, s), 7.90 (1H, s).

N^9 - and N^7 -(2-chloroethyl)-2-amino-6-chloropurine (2, 3). To a solution of **1** (10.0 g, 24 mmol) in 30 mL of CH_2Cl_2 was added 1-bromo-2-chloroethane (10 eq, 19.9 mL, 240 mmol). The reaction mixture was stirred at rt for about 1.5 h, during which time precipitation occurred. The solid was filtered, washed with cold CH_2Cl_2 , and dried under vacuum over CaSO_4 to yield a 5:1 mixture of **2** and **3** (3.99 g, 17 mmol, 71% combined yield). Recrystallization from CH_2Cl_2 (~20 mL) provided 2.66 g of the N^9 isomer, **3**, free of contamination with N^7 isomer **2**. The $^1\text{H-NMR}$ spectrum of **3** was consistent with that reported previously¹⁵: mp 189-191 °C; R_f = 0.65 (CHCl_3 :EtOAc:EtOH 1:1:1); $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ 4.04 (2H, t), 4.41 (2H, t), 6.99 (2H, s), 8.17 (1H, s). Compound **2**: R_f = 0.49 (CHCl_3 :EtOAc:EtOH 1:1:1); $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ 4.03 (2H, t), 4.67 (2H, t), 6.71 (2H, s), 8.42 (1H, s).

N^9 -(2-chloroethyl)guanine (4). A solution of 3 M $\text{HCl}_{(\text{aq})}$ (13 mL), containing **3** (2.5 g, 10.8 mmol), was refluxed for 1 h. The solution was cooled to rt and neutralized with

saturated $\text{NaHCO}_3(\text{aq})$. The resulting solid was filtered, washed with cold water, and dried under vacuum over CaSO_4 to yield **4** (2.31 g, 10.8 mmol, 100%): mp >250 °C; $R_f = 0.24$ ($\text{CHCl}_3:\text{EtOAc}:\text{EtOH}$ 1:1:1); $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ 3.97 (2H, t), 4.29 (2H, t), 6.53 (2H, s), 7.74 (1H, s), 10.70 (1H, s).

N^2 -(2-iodoethyl)guanine (5). A solution of **4** (100 mg, 4.68×10^{-4} mol) containing NaI (10 eq, 701 mg, 4.68×10^{-3} mol) in DMF (2-3 mL) was stirred at 75 °C for 1.5 h. The DMF was removed under vacuum. The resulting solid was triturated with water, filtered, washed with water, and dried under vacuum over CaSO_4 to yield **5** (110 mg, 3.61×10^{-4} mol, 77%): mp >250 °C; $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ 3.56 (2H, t), 4.29 (2H, t), 6.49 (2H, s), 7.72 (1H, s), 10.59 (1H, s).

2-amino-9-(2-(benzylamino)ethyl)-1H-purin-6(9H)-one (6). Benzylamine (4 eq, 1.87×10^{-3} mol 204 μL) was added to a solution of **4** (100 mg, 4.68×10^{-4} mol) containing NaI (21 mg, 1.40×10^{-4} mol) in $\text{DMSO}-d_6$ (~1 mL). The solution was then stirred for 15 h at 75 °C. After cooling the reaction mixture to rt, acetone (~20 mL) was added, resulting in precipitation. Addition of acetone resulted in precipitation. The solid was filtered, washed with acetone, and dried under vacuum over CaSO_4 to yield **6** (47 mg, 1.65×10^{-4} mol, 35%): $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ 3.24 (2H, t), 4.11 (1H, s), 4.28 (2H, t), 6.66 (2H, s), 7.43 (5H, m), 7.70 (1H, s), 8.77 (1H, s), 10.76 (1H, s).

2-amino-9-(2-(ethylthio)ethyl)-1H-purin-6(9H)-one (7). NaI (21 mg, 1.40×10^{-4} mol) and **4** (100 mg, 4.68×10^{-4} mol) were added to a solution of NaOH (4 eq, 1.87×10^{-3} mol,

75 mg) and ethanethiol (4 eq, 1.87×10^{-3} mol, 138 μ L) in DMSO (1 mL). The resulting solution was stirred at 75 °C for 1 h and then cooled to rt. Water (~20 mL) and glacial acetic acid (0.1 mL) were added until precipitation occurred. The resulting solid was filtered, washed with water, and dried under vacuum over CaSO₄ to yield **7** (66 mg, 2.76×10^{-4} mol, 59%): ¹H-NMR (DMSO-*d*₆, referenced to HOD δ 3.30) δ 1.09 (3H, t), 2.45 (2H, q) 2.82 (2H, t), 4.05 (2H, t), 6.39 (2H, s), 7.64 (1H, s), 10.51 (1H, s).

2-(2-amino-6-oxo-1H-purin-9(6H)-yl)ethyl benzoate (8). A solution of **4** (100 mg, 4.68×10^{-4} mol) containing NaI (21 mg, 1.40×10^{-4} mol) and sodium benzoate (4 eq, 1.87×10^{-3} mol, 270 mg) in DMSO-*d*₆ (2-3 mL) was stirred at 120-130 °C for 3.5 h. Water (~20 mL) was added to the hot reaction mixture and a precipitate formed. The solid was filtered, washed with water, and dried under vacuum over CaSO₄ to yield **8** (54 mg, 1.80×10^{-4} mol, 39%): R_f = 0.32 (CHCl₃:EtOAc:EtOH 1:1:1); ¹H-NMR (DMSO-*d*₆) δ 4.36 (2H, t), 4.56 (2H, t), 6.47 (2H, s), 7.50 (2H, t), 7.65 (2H, t), 7.77 (1H, s), 7.91 (2H, d), 10.58 (1H, s).

2-amino-9-vinyl-1H-purin-6(9H)-one (9). A solution of **4** (100 mg, 4.68×10^{-4} mol) containing NaI (21 mg, 1.40×10^{-4} mol) in DMSO (1 mL) was treated with NaOH (4 eq, 1.87×10^{-3} mol, 75 mg) and stirred at 75-85 °C for 1.5 h. The resulting precipitate was cooled to rt and dissolved in water (~5 mL). Precipitation occurred following addition of glacial acetic acid (~1 mL). The purple solid was filtered, washed with water, and dried under vacuum over CaSO₄ to yield **9** (68 mg, 3.84×10^{-4} mol, 82%): ¹H-NMR (DMSO-*d*₆) δ 5.02 (1H, d), 5.85 (1H, d), 6.57 (2H, s), 7.05 (1H, q), 8.08 (1H, s), 10.73 (1H, s).

ACKNOWLEDGMENT

For financial support, we thank Union College, Fäizer SURF, and the Research Corporation.

REFERENCES

1. Kelley, J. L.; Krochmal, M. P.; Schaeffer, H. J. *J. Med. Chem.* **1981**, *24*, 1528-1531.
2. Martin, J. C.; Jeffrey, G. A.; McGee, D. P. C.; Tippie, M. A.; Smee, D. F.; Mathews, T. R.; Verheyden, J. P. H. *J. Med. Chem.* **1985**, *28*, 358-362.
3. Kim, C. V.; Luh, B. Y.; Martin, J. C. *J. Med. Chem.* **1990**, *33*, 1797-1800.
4. Hury, D. M.; Okabe, M. *Chem. Rev.* **1992**, *92*, 1745-1768.
5. Franchetti, P.; Sheikha, G. A.; Capellacci, L.; Grifantini, M.; De Montis, A.; Piras, G.; Loi, A. G.; La Colla, P. *J. Med. Chem.* **1995**, *38*, 4007-4013.
6. Hakimelahi, G. H.; Ly, T. W.; Moosavi-Movahedi, A. A.; Jain, M. L.; Zakerinia, M.; Davari, H.; Mei, H.; Sambaiah, T.; Moshfegh, A. A.; Hakimelahi, S. *J. Med. Chem.* **2001**, *44*, 3710-3720.
7. Field, H. J.; Bell, S. E.; Elion, G. B.; Nash, A. A.; Wildy, P. *Antimicrobial Agents and Chemotherapy* **1979**, *15*, 554-561.
8. Biron, K. K.; Noblin, J. E.; De Miranda, P.; Elion, G. B. *Antimicrobial Agents and Chemotherapy* **1982**, *21*, 44-50.
9. Colla, L.; De Clercq, E.; Bussom, R.; Vanderhaeghe, H. *J. Med. Chem.* **1983**, *26*, 602-604.
10. Krenitsky, T. A.; Hall, W. W.; De Miranda, P.; Beauchamp, L. M.; Schaeffer, H. J.; Whiteman, P. D. *Proc. Natl. Acad. Sci. USA* **1984**, *81*, 3209-3213.
11. Golankiewicz, B.; Ostrowski, T.; Goslinski, T.; Januszczuk, P.; Zeidler, J.; Baranowski, D.; De Clercq, E. *J. Med. Chem.* **2001**, *44*, 4284-4287.
12. Tippie, M. A.; Martin, J. C.; Smee, D. F.; Mathews, T. R.; Verheyden, J. P. H. *Nucleosides Nucleotides* **1984**, *3*, 525-535.
13. Lai, C. L.; Rosmawati, M.; Lao, J.; Van Vlierberghe, H.; Anderson, F. H.; Thomas, N.; Dehertogh, D. *Gastroenterology* **2002**, *123*, 2135-2140.
14. De Clercq, E. *J. Antimicrob. Chemother.* **1993**, *32 Suppl A*, 121-132.
15. Ranzzaeva, N.; Alksnis, E.; Goldberg, Y.; Lidaks, M. *Synthetic Communications* **1989**, *19*, 3121-3128.
16. Borowski, P.; Niebuhr, A.; Mueller, O.; Bretner, M.; Felczak, K.; Kulikowski, T.; Schmitz, H. *Journal of Virology* **2001**, *75*, 3220-3229.
17. Choudary, B. M.; Geen, G. R.; Kinsey, P. M.; Parratt, M. J.; Dales, J. R. M.; Johnson, G. P.; O'Donnell, S.; Tudor, D. W.; Woods, N. *Nucleosides Nucleotides* **1996**, *15*, 981-994.

18. Torii, T.; Shiragami, H.; Yamashita, K.; Suzuki, Y.; Hijiya, T.; Kashiwagi, T.; Izawa, K. *Tetrahedron* **2006**, *article in press*.
19. Freer, R.; Geen, G. R.; Ramsay, T. W.; Share, A. C.; Slater, G. R.; Smith, N. M. *Tetrahedron* **2000**, *56*, 4589-4595.
20. Bisacchi, G. S.; Singh, J.; Godfrey, Jr., J. D.; Kissick, T. P.; Mitt, T.; Malley, M. F.; Di Marco, J. D.; Gougoutas, J. Z.; Mueller, R. H.; Zahler, R. J. *Org. Chem.* **1995**, *60*, 2902-2905.






Figure 1: various N⁹-substituted anti-virals.



Scheme 1. Reagents and Conditions: (a) 1.5 M TBAH, CH_2Cl_2 , rt, 30 min (b) $\text{Br}(\text{CH}_2)_2\text{Cl}$, CH_2Cl_2 , rt, 1.5 h (c) 3 M $\text{HCl}_{(\text{aq})}$, reflux, 1 h.

Scheme 2.




Title for running head (current title is less than 50 characters):

Efficient Synthesis of N^p-alkylguanines

Graphical Abstract:

An efficient synthesis of N^9 -(2-chloroethyl)guanine from 2-amino-6-chloropurine is reported. Subsequent displacement reactions allowed for the preparation of various N^9 -substituted guanines.



Evaluation of a More Highly Conjugated Analog of Guanidinium-Rich Molecular Transporters Using a pH Dependent Fluorescence Assay

David E. Olson^a, Barbara Danowski^b, and Joanne D. Kehlbeck^{a*}

Department of Chemistry^a and Department of Biological Sciences^b
Union College, Schenectady, NY 12308

Abstract:

The importance of the guanidino functional group in the cellular uptake of guanidinium-rich molecular transporters has been thoroughly demonstrated. Its ability to act as a bidentate hydrogen bond donor appears to play a key role in this process, but the effect of polarizability on cellular internalization has not been determined. We report the synthesis of a peptoid molecular transporter containing more highly conjugated guanine headgroups and its subsequent evaluation using a pH dependent fluorescence assay.

Introduction:

An important role of biological membranes is to exclude harmful substances from the interior of the cell. However, this defense mechanism also prevents the passive cellular uptake of many useful therapeutics. Currently, the design of drugs limits their physical properties to a very narrow range of hydrophobicities, as they must be both soluble in

* Correspondence: J. D. Kehlbeck, Department of Chemistry, Union College, Schenectady, NY 12308, United States of America; E-mail: kehlbecj@union.edu

polar extracellular fluids and sufficiently nonpolar to passively diffuse through the lipid bilayer of the cell. These constraints impose limitations on the design of therapeutics, and consequently, may hinder their effectiveness.

A class of compounds, collectively known as molecular transporters, has shown promising results in the area of drug delivery.¹ Many of these molecules are derived from naturally occurring proteins capable of traversing the cellular membrane.²⁻⁶ In particular, the nuclear transcription activator protein (Tat) encoded by HIV-1 has the ability to cross the plasma membrane, and its highly basic region, consisting of residues 49-57, has been shown to be primarily responsible for its cellular uptake.⁷⁻¹¹

Analogs of this highly basic region enter cells by a mechanism that is currently unresolved.¹²⁻¹⁹ They typically consist of cationic residues that serve to increase the water solubility of their molecular cargo. Therefore, these molecular transporters increase the bioavailability of existing drugs as well as allow new drugs to be designed without the structural limitations that have hindered the development of current therapeutics.

Various molecular transporters have been shown to effectively traverse cellular membranes despite their structural dissimilarities. Nonnatural D-peptides²⁰, as well as molecular transporters containing peptoid²⁰ or oligocarbamate²¹ backbones have all been shown to efficiently enter cells. Also, use of aminocaproic acid spacers between residues²² and an increase in the side chain lengths²⁰ improved cellular uptake. This

broad range of structural features appears to be inconsistent with a receptor-mediated process. However, the guanidinium moiety is a common structural feature in all of these molecular transporters.

The homopolymers of lysine, ornithine, and histidine, cationic transporter molecules that lack the guanidinium group, have been shown to cross the lipid bilayer of the cell with only limited success.²³⁻²⁴ However, arginine homopolymers are internalized very effectively.²⁴ This suggests that it is the unique properties of the guanidinium group that allow for the efficient cellular uptake of guanidinium-rich molecular transporters.

Rothbard *et al.* have proposed that it is the ability of the guanidinium group to act as a bidentate hydrogen bond donor that enables guanidinium-rich molecular transporters to be internalized.¹⁵ Presumably, the positively charged guanidinium group would associate with cell surface moieties such as sulfates or phosphates through a bidentate hydrogen bond interaction. This less polar ion pair would then be able to diffuse through the nonpolar lipid bilayer of the cell.

The current study seeks to explore another unique feature, namely the polarizability of the guanidinium group, that might also contribute to the effectiveness of guanidinium-rich molecular transporters. Cellular uptake studies were performed using a molecular transporter rich in guanine, a more highly conjugated analog of the guanidino group. We hypothesized that this increase in conjugation, leading to an increase in polarizability, might affect the extent to which this new transporter is internalized.

Also, by exploiting the pH sensitivity of fluorescein²⁵⁻²⁸, we hoped to clarify the extent to which the fluorescent conjugates of molecular transporters are truly internalized. It has been shown that the emission of fluorescein can be selectively quenched on the exterior of cells following a lowering of the local pH²⁹. This procedure does not affect the intensity of fluorescence resulting from internalized fluorescein and can therefore be used to qualitatively compare the amount of fluorescent probe that has been internalized to that which has merely adhered to the cell surface. Most studies to date involving molecular transporters have used flow cytometry to monitor internalization and have had faith that numerous washes removed all externally adhered transporter. This pH dependent fluorescence assay provides a means for qualitatively determining the fluorescence due to cell surface adhesion.

Experimental:

General. Rink amide-MBHA resin was purchased from NovaBiochem, while 2-amino-6-chloropurine was purchased from AB CHEM TECHNOLOGIES, LLC. All other reagents were purchased from Aldrich and used without further purification.

Fl-aca-N-hxg(NH₂)₉-CONH₂ (1). A modified procedure based on a microwave assisted³⁰ sub-monomer approach to peptoid synthesis³¹⁻³³ was employed. Peptoids were manually synthesized in fritted vessels using mechanical agitation to ensure mixing of the resin. A chloranil test for secondary amines was performed at each stage of the synthesis

in order to evaluate the progress of the reactions.³⁴ Fmoc protected Rink amide resin (100 mg) was agitated in DMF (4-5 mL) for 30 min and afforded approximately 50 μmol of exposed amine functional groups following treatment with 20% (v/v) piperidine/DMF (1-2 mL for 1 min, 2-3 mL for 10 min, and 2-3 mL for 10 min). The resin was then washed with DMF (2-3 mL x 5) before being treated with a solution of bromoacetic acid (20 eq) and DIC (26 eq) in 4 mL of DMF. The reaction mixture was microwaved at 30% (2 x 15 s with manual agitation in between) using a Panasonic NN-S443 microwave oven and agitated for an additional 45 mins. Next, the resin was washed with DMF (2-3 mL x 5) and treated with a solution of DMF (4 mL) containing *N*-Boc-1,6-hexanediamine (17 eq). The reaction mixture was microwaved at 30% (2 x 15 s with manual agitation in between) and agitated for an additional 45 mins. The resin was then washed with DMF (2-3 mL x 5). The bromoacetic acid coupling and amine substitution steps were repeated until a 9-residue oligomer had been obtained. After the addition of 6-(Fmoc-amino)caproic acid (20 eq) and DIC (26 eq) in DMF (4 mL), the reaction mixture was microwaved at 30% (2 x 15 s with manual agitation in between). The vessel was then agitated for an additional 45 mins. Conjugation of fluorescein-5-isothiocyanate (0.2 mmol) to the transporter molecule in the presence of DIEA (2 mmol) was complete after a 15-hour incubation period. Care was taken to avoid unnecessary exposure of the fluorescein moiety to light. Next, the resin was drained of excess fluorophore and washed with DMF (3 x 5 mL) and dichloromethane (5 x 5 mL). The resin was then air dried by applying a vacuum for 10 min. Cleavage from the resin was achieved using a 95:5 (v/v) TFA/triisopropylsilane cocktail mixture. After 4 hours the product was collected and the TFA was removed *in vacuo*. The crude oil was triturated with cold

ether (20 mL) and centrifuged. The ether was removed by decantation. The resulting orange solid will be purified by RP-HPLC, isolated by lyophilization, and characterized by electrospray mass spectrometry. The concentration of **1** was determined from a Beer's Law plot using the extinction coefficient of fluorescein ($\epsilon = 72,000 \text{ M}^{-1} \text{ cm}^{-1}$, 494 nm).

Fl-aca-N-hxg(Guanidinium)₉-CONH₂ (2). Perguanidinylation of **1** by the method of Wender *et al.*²⁰ afforded **2**, which will be purified by RP-HPLC, isolated by lyophilization, and characterized by electrospray mass spectrometry. The concentration of **2** was determined from a Beer's Law plot using the extinction coefficient of fluorescein ($\epsilon = 72,000 \text{ M}^{-1} \text{ cm}^{-1}$, 494 nm). However, care was taken to ensure that the solution of **2** was neutral before absorbance measurements were taken.

Fl-aca-N-hxg(Guanine)₉-CONH₂ (3). The procedure for the synthesis of **1** was followed with the exception that *N*-Boc-1,3-propanediamine was used in place of *N*-Boc-1,6-hexanediamine. Next, the peptoid will be treated with *N*⁹-(2-chloroethyl)guanine and NaI (30 mol %) in DMF. *N*⁹-(2-chloroethyl)guanine was prepared by the method of Olson *et al.*³⁵ Compound **3** will be purified by RP-HPLC, isolated by lyophilization, and characterized by electrospray mass spectrometry. The concentration of **3** will be determined from a Beer's Law plot using the extinction coefficient of fluorescein ($\epsilon = 72,000 \text{ M}^{-1} \text{ cm}^{-1}$, 494 nm).

Preliminary Results:

Live Swiss 3T3 mouse embryo fibroblast cells were incubated in OPTIMEM containing either 2 μM of **1** (negative control) or **2** (positive control) for 60 min at 37 $^{\circ}\text{C}$, and the results are shown in Figure 1. Very little cellular uptake of **1** is observed, as expected. Compound **2** seems to be readily internalized and appears to be localized in endocytic vesicles.



Negative Control (1)



Positive Control (2)

Figure 1: Swiss 3T3 mouse embryo fibroblast cells incubated with either 2 μM of compound **1** or **2**.

A fluorescence quenching assay will also be employed in this study. The fluorescence of fluorescein will be quenched following addition of acid to the incubation media. This procedure should not affect internal pH. However, a control study was performed to assess the effectiveness of this pH dependent fluorescence quenching assay. Swiss 3T3 mouse embryo fibroblast cells were incubated with free fluorescein isothiocyanate (FITC). Fluorescent images were taken using confocal microscopy prior to and following the addition of acid to the incubation media. The results can be seen in Figure

2. Fluorescent signal observed after the addition of acid is presumably a result of internalized fluorophore while that observed prior to the addition of acid is a result of both internalized fluorophore and that which has adhered to the cell surface.



pH = 7.35




pH = 6.50

Figure 2: Swiss 3T3 mouse embryo fibroblast cells incubated with FITC (pre- and post-addition of acid to the incubation media).

References:

21. Bonetta, L. *The Scientist* **2002**, *16*, 38.
22. Frankel, A. D.; Pabo, C. O. *Cell* **1988**, *55*, 1189-1193.
23. Green, M.; Loewenstein, P. M. *Cell* **1988**, *55*, 1179-1188.
24. Derossi, D.; Joliot, A. H.; Chassaing, G.; Prochiantz, A. *J. Biol. Chem.* **1994**, *269*, 10444-10450.
25. Derossi, D.; Calvet, S.; Trembleau, A.; Brunissen, A.; Chassaing, G.; Prochiantz, A. *J. Biol. Chem.* **1996**, *271*, 18188-18193.
26. Dom, G.; Shaw-Jackson, C.; Matis, C.; Bouffioux, O.; Picard, J. J.; Prochiantz, A.; Mingeot-Leclercq, M.; Brasseur, R.; Rezsöházy, R. *Nucleic Acids Research* **2003**, *31*, 556-561.
27. Anderson, D. C.; Nichols, E.; Manger, R.; Woodle, D.; Barry, M.; Fritzberg, A. R. *Biochem. Biophys. Res. Commun.* **1993**, *194*, 876-884.
28. Fawell, S.; Seery, J.; Daikh, T.; Moore, C.; Chen, L. L.; Pepinsky, B.; Barsoum, J. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 664-668.
29. Pepinsky, R. B.; Androphy, E. J.; Corina, K.; Brown, R.; Barsoum, J. *DNA Cell Biol.* **1994**, *13*, 1011-1019.
30. Vivés, E.; Granier, C.; Prevot, P.; Leblue, B. *Lett. Pept. Sci.* **1997**, *4*, 429-436.

31. Vivés, E.; Brodin, P.; Leblue, B. *J. Biol. Chem.* **1997**, *272*, 16010-16017.
32. Sakai, N.; Matile, S. *J. Am. Chem. Soc.* **2003**, *125*, 14348-14356.
33. Vives, E. *Journal of Molecular Recognition* **2003**, *16*, 265-271.
34. Vives, E.; Richard, J. P.; Rispal, C.; Lebleu, B. *Current Protein & Peptide Science* **2003**, *4*, 125-132.
35. Rothbard, J. B.; Jessop, T. C.; Lewis, R. S.; Murray, B. A.; Wender, P. A. *J. Am. Chem. Soc.* **2004**, *126*, 9506-9607.
36. Potocky, T.; Menon, A. K.; Gellman, S. H. *J. Biol. Chem.* **2003**, *278*, 50188-50194.
37. Fuchs, S. M.; Raines, R. T. *Biochemistry* **2004**, *43*, 2438-2444.
38. Rothbard, J. B. *Advanced Drug Delivery Reviews* **2005**, *57*, 495.
39. Futaki, S. *Biopolymers (Peptide Science)* **2006**, *84*, 241-249.
40. Wender, P. A.; Mitchell, D. J.; Pattabiraman, K.; Pelkey, E. T.; Steinman, L.; Rothbard, J. B. *PNAS* **2000**, *97*, 13003-13008.
41. Wender, P. A.; Rothbard, J. B.; Jessop, T. C.; Kreider, E. L.; Wylie, B. L. *J. Am. Chem. Soc.* **2002**, *124*, 13382-13383.
42. Rothbard, J. B.; Kreider, E.; VanDeusen, C. L.; Wright, L.; Wylie, B. L.; Wender, P. A. *J. Med. Chem.* **2002**, *45*, 3612-3618.
43. Ryser, H. J.-P. *Nature (London)* **1967**, *215*, 934-936.
44. Mitchell, D. J.; Kim, D. T.; Steinman, L.; Fathman, C. G.; Rothbard, J. B. *J. Pept. Res.* **2000**, *56*, 318-325.
45. Unruh, J. R.; Gokulrangan, G.; Wilson, G. S.; Johnson, C. K. *Photochemistry and Photobiology* **2004**, *81*, 682-690.
46. Hammer, M.; Schweitzer, D.; Richter, S.; Königsdröffer, E. *Physiol. Meas.* **2005**, *26*, N9-N12.
47. Liu, Z.; Gao, S.; Chen, T. *Journal of Polymer Science Part A: Polymer Chemistry* **2005**, *43*, 3447-3453.
48. Levitz, S. M.; Nong, S.; Seetoo, K. F.; Harrison, T. S.; Speizer, R. A.; Simons, E. R. *Infection and Immunity* **1999**, *67*, 885-890.
49. Mandouh, Z.; Chen, X.; Pierini, L. M.; Maxfield, F. R.; Muller, W. A. *Nature* **2003**, *421*, 748-753.
50. Olivos, H. J.; Alluri, P. G.; Reddy, M. M.; Salony, D.; Kodadek, T. *Org. Lett.* **2002**, *4*, 4057-4059.
51. Murphy, J. E.; Uno, T.; Hamer, J. D.; Dwarki, V.; Zuckermann, R. N. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 1517-1522.
52. Simon, R. J.; Kania, R. S.; Zuckermann, R. N.; Huebner, V. D.; Jewell, D. A.; Banville, S.; Ng, S.; Wang, L.; Rosenberg, S.; Marlowe, C. K., et al. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 9367-9371.
53. Zuckermann, R. N.; Kerr, J. M.; Kent, S. B. H.; Moos, W. H. *J. Am. Chem. Soc.* **1992**, *114*, 10646-10647.
54. Chan, W. C.; White, P. D. *Fmoc Solid Phase Peptide Synthesis*. Oxford. **2000**.
55. Olson, D. E.; Reid, J. G.; Kehlbeck, J. D. Unpublished Results **2006**.



Scheme 1. Reagents and Conditions: (a) bromoacetic acid, DIC, DMF (b) *N*-Boc-1,6-hexanediamine or *N*-Boc-1,3-propanediamine, DMF (c) 6-(Fmoc-amino)caproic acid (d) piperidine, DMF (e) FITC, DIEA, DMF (f) 95:5 TFA/TIS (g) pyrazole-1-carboxamide hydrochloride, Na_2CO_3 (h) *N*²-(2-chloroethyl)guanine, NaI, DMF.

ACKNOWLEDGMENTS

I would like to thank my research advisors, Prof. Joanne D. Kehlbeck and Prof. J. Gregory Reid for their guidance and support. Their commitment to teaching and quality research has had a huge impact on my decision to pursue a career in academia. The great scientist Galileo Galilei once said, "We cannot teach people anything; we can only help them discover it within themselves." Their inspiration has given me confidence in myself, and I hope that one day I will be able to do the same for my students.

I am indebted to Prof. Kehlbeck for her belief in me. She has always given me enough freedom to forge my own path in science, and I owe my independence to her. The academic environment that she created nurtured my growth as a scientist, and I hope to emulate her enthusiasm for learning.

To Prof. Reid, I owe much of my skill as a synthetic organic chemist. I am extremely grateful for his patience and desire to teach me the skills of the art. His hardwork and dedication are surely and inspiration to us all.

Next, I would like to thank all of the past, present, and honorary members of the Kehlbeck research lab. They are: Eric Dimise ('05), Sarah-Jo Stimpson ('05), James Miller ('05), Jim Bush ('05), Sarah Sparks ('06), Kristina Gehring ('06), and Aaron Almeida ('07). In particular, I would like to thank Sarah for her friendship and for being so patient with me.

I extend my sincerest thanks to the entire Union College Chemistry Department. Everyone in the department was extremely helpful during my time at Union, and I hope that one day I will return to witness the continuing growth of a truly outstanding program in chemistry.

Finally, I dedicate this work to my parents Richard and Margaret Olson for their love and support. Their guidance has helped me grow to become the scientist and person that I am today, and there are no two people whom I admire more.

David E. Olson
June 2006